simulator software version 16 release 1 (Simcyp)
90
Structured Review
Simcyp
simulator software version 16 release 1
Simulator Software Version 16 Release 1, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/16+simulation+software/simulator+version+15/pm30300922-149-9-15
Average 90 stars, based on 1 article reviews
Simulator Software Version 16 Release 1, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/16+simulation+software/simulator+version+15/pm30300922-149-9-15
Average 90 stars, based on 1 article reviews
simulator software version 16 release 1 - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
Construct:Article Title: PBPK modeling to predict drug‐drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction Article Snippet: To assess the prediction accuracy of the Article Title: Application of a Physiologically Based Pharmacokinetic Model to Predict Cefazolin and Cefuroxime Disposition in Obese Pregnant Women Undergoing Caesarean Section Article Snippet: An existing compound file for cefuroxime has been developed previously by Hsu et al. using the Article Title: Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex Article Snippet: PBPK models for VPA IR and ER formulations were constructed using Article Title: Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach Article Snippet: Available information on the metabolism and PK of brigatinib was utilized to develop the PBPK model for brigatinib using the Article Title: Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs Article Snippet: PBPK models were constructed in the Article Title: Advancements in Virtual Bioequivalence: A Systematic Review of Computational Methods and Regulatory Perspectives in the Pharmaceutical Industry Article Snippet: Xiao, Q. et al. [ ], 2015 , Cochrane Library , Repaglinide and pioglitazone , Antidiabetic , Protein Binding:Article Title: PBPK modeling to predict drug‐drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction Article Snippet: To assess the prediction accuracy of the Article Title: Application of a Physiologically Based Pharmacokinetic Model to Predict Cefazolin and Cefuroxime Disposition in Obese Pregnant Women Undergoing Caesarean Section Article Snippet: An existing compound file for cefuroxime has been developed previously by Hsu et al. using the Article Title: Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex Article Snippet: PBPK models for VPA IR and ER formulations were constructed using Article Title: Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach Article Snippet: Available information on the metabolism and PK of brigatinib was utilized to develop the PBPK model for brigatinib using the Article Title: Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs Article Snippet: PBPK models were constructed in the Article Title: Advancements in Virtual Bioequivalence: A Systematic Review of Computational Methods and Regulatory Perspectives in the Pharmaceutical Industry Article Snippet: Xiao, Q. et al. [ ], 2015 , Cochrane Library , Repaglinide and pioglitazone , Antidiabetic , |
